{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:01:58Z","timestamp":1791460918195,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T00:00:00Z","timestamp":1279152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/hr.2010.115","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T06:19:45Z","timestamp":1279174785000},"page":"872-875","source":"Crossref","is-referenced-by-count":24,"title":["Aldosterone, hypertension and heart failure: insights from clinical trials"],"prefix":"10.1038","volume":"33","author":[{"given":"John W","family":"Funder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,7,15]]},"reference":[{"key":"BFhr2010115_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"10","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 10: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"BFhr2010115_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"P Barter","year":"2007","unstructured":"Barter P, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B . Effects of Torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109\u20132122.","journal-title":"N Engl J Med"},{"key":"BFhr2010115_CR3","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH . Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism Type 1. J Clin Endocrinol Metab 2005; 90: 5070\u20135076.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFhr2010115_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ . Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243\u20131248.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2010115_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D . Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33\u201341.","journal-title":"N Engl J Med"},{"key":"BFhr2010115_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce P, Smith R, Smith AI . Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583\u2013585.","journal-title":"Science"},{"key":"BFhr2010115_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(88)90742-8","volume":"2","author":"CR Edwards","year":"1988","unstructured":"Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C . Localisation of 11 beta-hydroxysteroid dehydrogenase\u2014tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986\u2013989.","journal-title":"Lancet"},{"key":"BFhr2010115_CR8","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1210\/endo.137.12.8940344","volume":"137","author":"JW Funder","year":"1996","unstructured":"Funder JW, Myles K . Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinol 1996; 137: 5264\u20135268.","journal-title":"Endocrinol"},{"key":"BFhr2010115_CR9","doi-asserted-by":"publisher","first-page":"9202","DOI":"10.1073\/pnas.1633591100","volume":"100","author":"C Fjeld","year":"2003","unstructured":"Fjeld C, Birdsong W, Goodman R . Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 2003; 100: 9202\u20139207.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFhr2010115_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","volume":"35","author":"R Alzamora","year":"2000","unstructured":"Alzamora R, Michea L, Marusic ET . Role of 11 beta-hydroxysteroid dehydrogenase on nongenomic aldosterone effects in human arteries. Hypertens 2000; 35: 1099\u20131104.","journal-title":"Hypertens"},{"key":"BFhr2010115_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","volume":"93","author":"W Qin","year":"2003","unstructured":"Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG . A transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69\u201376.","journal-title":"Circ Res"},{"key":"BFhr2010115_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309\u20131321.","journal-title":"N Engl J Med"},{"key":"BFhr2010115_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","volume":"54","author":"AS Mihaildou","year":"2009","unstructured":"Mihaildou AS, Loan Le TY, Mardini M, Funder JW . Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertens 2009; 54: 1306\u20131312.","journal-title":"Hypertens"},{"key":"BFhr2010115_CR14","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/bjp.2008.229","volume":"154","author":"MJ Forrest","year":"2008","unstructured":"Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriguez W, Siegl PK, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker III M, West SH, White V, Woltmann RF . Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154: 1465\u20131473.","journal-title":"Br J Pharmacol"},{"key":"BFhr2010115_CR15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1210\/en.2008-1512","volume":"150","author":"X Hu","year":"2009","unstructured":"Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J . Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology 2009; 150: 2211\u20132219. San Francisco, June 2008, p. 38.","journal-title":"Endocrinology"},{"key":"BFhr2010115_CR16","first-page":"S452","volume":"118","author":"AM Capponi","year":"2008","unstructured":"Capponi AM, Clerk RG, Campos L, Perez A, Garriz JMR, Maugeais C, Niesor EJ . No increase in the in vitro production of aldosterone on the expression of CYP 11\u03b22 with the CETP modulation dalcetrapib (RO4607381\/JTT-7OS), in contrast with Torcetrapib. Circ 2008; 118: S452\u2013S452.","journal-title":"Circ"},{"key":"BFhr2010115_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1210\/en.2009-0136","volume":"150","author":"JW Funder","year":"2009","unstructured":"Funder JW . The off-target effects of Torcetrapib. Endocrinol 2009; 150: 221\u2013229.","journal-title":"Endocrinol"},{"key":"BFhr2010115_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/HJH.0b013e32831cf2c6","volume":"27","author":"P Manunta","year":"2009","unstructured":"Manunta P, Ferrandi M, Bianchi G, Hamlyn JM . Endogenous ouabain in cardiovascular function and disease. J Hypertens 2009; 27: 9\u201318.","journal-title":"J Hypertens"},{"key":"BFhr2010115_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1113\/jphysiol.2005.091801","volume":"569","author":"J Zhang","year":"2005","unstructured":"Zhang J, Lee MY, Cavalli M, Chen L, Berra-Romani R, Balke CW, Bianchi G, Ferrari P, Hamlyn JM, Iwamoto T, Lingrel JB, Matteson DR, Wier WG, Blaustein MP . Sodium pump \u03b12 subunits control myogenic tone and blood pressure in mice. J Physiol 2005; 569: 245\u2013256.","journal-title":"J Physiol"},{"key":"BFhr2010115_CR20","doi-asserted-by":"publisher","first-page":"15845","DOI":"10.1073\/pnas.0507358102","volume":"102","author":"I Dostanic-Larson","year":"2005","unstructured":"Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB . The highly conserved cardiac glycoside binding site of Na, K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci USA 2005; 102: 15845\u201315850.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFhr2010115_CR21","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"D Levy","year":"2004","unstructured":"Levy D, Rocha R, Funder JW . Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736\u20132740.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2010115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2010115","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2010115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:05:26Z","timestamp":1684429526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2010115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,15]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFhr2010115"],"URL":"https:\/\/doi.org\/10.1038\/hr.2010.115","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,15]]}}}